Viking Therapeutics has initiated its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1 and GIP receptor agonist, targeting obesity and obesity with type 2 diabetes. This marks a significant advancement for the company, moving its promising oral drug candidate into late-stage trials, which could have substantial implications for the competitive obesity drug market.
Viking Therapeutics has announced the initiation of its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1 and GIP receptor agonist. This is a critical development as it moves their oral obesity drug candidate into late-stage trials, a significant de-risking event for the company. If successful, VK2735 could become a major competitor in the rapidly growing obesity and metabolic disorders market, currently dominated by injectables from Eli Lilly (LLY) and Novo Nordisk (NVO). For VKTX, this represents a long-term opportunity for substantial revenue growth, while for LLY and NVO, it poses a potential threat of increased competition, particularly in the oral drug segment. Traders should watch for initial enrollment progress and future data readouts as these will be key catalysts.